| EPB161 | Switching EFV/FTC/TDF to B/F/TAF or generic EFV/FTC/TDS in virologically suppressed adults with human immunodeficiency virus: a 96-week retrospective cohort | E-poster | Regimen simplification and switch studies |
| EPB162 | Integrase resistance emergence with dolutegravir/lamivudinewith prior HIV-1 suppression | E-poster | Regimen simplification and switch studies |
| EPB163 | Real-world HIV renal outcomes with TDF-to-TAF switch | E-poster | Regimen simplification and switch studies |
| EPB164 | Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care | E-poster | Regimen simplification and switch studies |
| EPB165 | Changes in inflammatory biomarkers and baseline variables after switching to dolutegravir/lamivudine (DTG/3TC) in 2 randomized clinical trials of virologically suppressed adults: 48-week pooled analysis | E-poster | Regimen simplification and switch studies |
| EPB166 | Rapid tenofovir-lamivudine-dolutegravir transition in Papua New Guinea: a virtual approach to antiretroviral prescriber refresher trainings during a global pandemic | E-poster | Regimen simplification and switch studies |
| EPB167 | Intermittent doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains viral suppression in real life in controlled HIV-infected patients | E-poster | Regimen simplification and switch studies |
| EPB168 | Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study | E-poster | Regimen simplification and switch studies |
| EPB169 | Efficacy and safety of switching to Dolutegravir/Lamivudine by baseline regimen in virologically suppressed adults: 48-week pooled analysis | E-poster | Regimen simplification and switch studies |
| EPB170 | Changes innonalcoholicfatty liverdiseasespectrum and metabolic markers in people with HIV after switching to a raltegravir-based regimen | E-poster | Regimen simplification and switch studies |